Clinically significant drug interactions with atypical antipsychotics

CNS Drugs

Volumn 27, Issue 12, 2013, Pages 1021-1048

  Kennedy, William Klugh ^a,c,f   Jann, Michael W ^b   Kutscher, Eric C ^d,e  

^a MERCER UNIVERSITY   (United States)

^b University of North Texas System College of Pharmacy   (United States)

^c MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SOUTH DAKOTA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTH DAKOTA   (United States)

^f MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CIMETIDINE; CYTOCHROME P450; DILTIAZEM; FLUOXETINE; FLUVOXAMINE; ILOPERIDONE; KETOCONAZOLE; LAMOTRIGINE; LURASIDONE; PAROXETINE; PHENOBARBITAL; PROTEINASE INHIBITOR; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

AREA UNDER THE CURVE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG GLUCURONIDATION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SMOKING;

ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; PROTEIN BINDING; PSYCHOTIC DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 84890483830     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0114-6     Document Type: Review

References (166)

1. Zumbrunnen TL, Jann MW. Drug interactions with antipsychotic agents. CNS Drugs. 1998;9:381-401.
2. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003;28:99-111.
3. Spina E, DeLeon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100:4-22.
4. Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharm Bull. 2007;40:77-97.
5. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome P450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9:410-8.
6. Raggi MA, Mandrioli R, Sabbioni C, Pucci V. Atypical antipsychotics pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. Curr Med Chem. 2004;11:279-96.
7. Perel JM, Jann MW. Antipsychotics. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, editors. Applied pharmacokinetics and pharmacodynamics. Baltimore: Lippincott, Williams and Wilkins; 2006. p. 813-38.
8. Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. Atypical antipsychotic metabolism and excretion. Curr Drug Metab. 2010;11:516-25.
9. Mauri MC, Volonteri LS, Colasanti A, Fiorentino A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics. Clin Pharmacokinet. 2007;46:359-88.
10. DeVane CL. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharm Bull. 2002;36:5-21.
11. Harrison TS, Scott LJ. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. CNS Drugs. 2006;20:1027-52.
12. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Clin Pharmacokinet. 1999;37:177-93.
13. Garnett WR, Anderson GD, Collins RJ. Antiepileptic drups. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, editors. Applied pharmacokinetics and pharmacodynamics. Baltimore: Lippincott, Williams and Wilkins; 2006. p. 491-511.
14. Alt Burstein. Lamotrigine. Pharmacotherapy. 1995;15:129-43.
15. Liston HL, Markowitz JS, DeVane CL. Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol. 2001;21:500-15.
16. Markowitz JS, DeVane CL, Liston HL, Boulton DS, Risch SC. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clin Pharmacol Ther. 2002;71:30-8.
17. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkenson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101:289-94.
18. Linnet K, Ejsing TB. A review on the impact of P-glycoprotein on the penetration of drugs into the brain: focus on psychotropic drugs. Eur Neuropsychopharmacol. 2008;18:157-69.
19. Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009;323:1718-22.
20. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol. 1999;39:1203-11.
21. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In-vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71:163-9.
22. Moons T, de Roo M, Clees S, Dom G. Relationship between P-glycoprotein and second generation antipsychotics. Pharmacogenomics. 2011;12:1193-211.
23. Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, DeVane CL. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropharmacology. 2004;29:551-7.
24. Kirschbaum KM, Uhr M, Holtoewer D, Namendorf C, Pietrzik C, Hiemke C, Schmitt U. Pharmacokinetics of acute and subchronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology. 2010;59:474-9.
25. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, DeVane CL. Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology. 2007;32:757-64.
26. Crismon ML, Argo TR, Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 8th ed. New York: McGraw Hill Medical; 2011. p. 1147-72.
27. Rim CL, Gitlin MJ. Ziprasidone, monoamine oxidase inhibitors, and the serotonin syndrome. J Clin Psychopharmacol. 2010;30:470-1.
28. Naso AR. Optimizing patient safety by preventing combined use of intramuscular olanzapine and parenteral benzodiazepines. Am J Health-Syst Pharm. 2008;65:1180-3.
29. Zacher JL, Roche-Desilets J. Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam. J Clin Psychiatry. 2005;66:1614-5.
30. Bushe CJ, Taylor M, Mathew M. Intramuscular olanzapine - a UK case series of early cases. Ann Gen Psychiatry. 2007;6:11. doi: 10.1186/1744-859X-6-11.
31. Swainston Harrison T, Scott LJ. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. CNS Drugs. 2006;20:1027-52.
32. AstraZeneca. Seroquel (quetiapine): package insert. Wilmington: AstraZeneca; 2010.
33. Aghaieniua N, Brahm NC, Lussier KM, Washington NB. Probable quetiapine-mediated prolongation of the QT interval. J Pharm Pract. 2011;24:506-12.
34. Vieweg WV, Schneider RK, Wood MA. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatr Scand. 2005;112:318-22.
35. Kurth J, Maguire G. Pediatric case report of quetiapine overdose and QTc prolongation. Ann Clin Psychiatry. 2004;16:229-31.
36. Hough DW, Natarajan J, Vandelbosch A, Rossenu S, Kramer M, Eerdekens M. Evaluation of the effect of paliperidone extended release and quetiapine on correct QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2011;26:25-34.
37. Ozeki Y, Fujii K, Kurimoto N, et al. QTc prolongation and antipsychotic medications in a sample of 1,017 patients with schizophrenia. Prog Neuropsychopsychopharmacol Biol Psychiatry. 2010;34:401-405.
38. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-65.
39. Nazirizadeh Y, Vogel F, Bader W, et al. Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol. 2010;66:797-803.
40. Sparshatt A, Taylor D, Patel MX, Kapur S. A systematic review of aripiprazole - dose, plasma concentrations, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010;71:1447-56.
41. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol. 2003;43:443-69.
42. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65:189-210.
43. Sunovion. Latuda (lurasidone): package insert. Marlborough: Sunovion; 2010.
44. Arif SA, Mitchell MM. Iloperidone: a new drug for the treatment of schizophrenia. Am J Health-Syst Pharm. 2011;68:301-8.
45. Marino J, Caballero J. Iloperidone for the treatment of schizophrenia. Ann Pharmacother. 2010;44:863-70.
46. Marino J, Caballero J. Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy. 2008;28:1283-98.
47. Vanda Pharmaceuticals. Fanapt (iloperidone): package insert. Rockville: Vanda Pharmaceuticals; 2009.
48. Weber J, McCormack PL. Asenapine. CNS Drugs. 2009;23:781-92.
49. Chwieduk CM, Scott LJ. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder. CNS Drugs. 2011;25:251-67.
50. Organon. Saphris (asenapine): package insert. Whitehouse: Organon; 2011.
51. Otsuka Pharmaceuticals. Abilify (aripiprazole): package insert. Tokyo: Otsuka Pharmaceuticals; 2009.
52. Bowles TM, Levin GL. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother. 2003;37:687-94.
53. Pfizer, Inc. Geodon (ziprasidone): package insert. New York: Pfizer, Inc.; 2009.
54. Janssen, a Division of Ortho-McNeil Pharmaceuticals. Invega (paliperidone): package insert. Titusville: Janssen; 2010.
55. Wang SM, Han SC, Lee SJ, Patkar AA, Pae CU, Fleishhacker WW. Paliperidone: a review of clinical trial data and clinical implications. Clin Drug Investg. 2012;32:497-512.
56. Berwaerts J, Cleton A, Herben V, van de Vliet I, Chang I, van Hoek P, Eerdekens M. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry. 2009;42:158-63.
57. Thyssen A, Cleton A, Talluri K, Leempoels J, Janssens L, Boom S, Eerdekens M. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol Clin Exp. 2009;24:532-9.
58. Janssen, a Division of Ortho-McNeil Pharmaceuticals. Risperidal (risperidone): package insert. Titusville: Janssen; 2010.
59. Eli Lilly and Company. Zyprexa (olanzapine): package insert. Indianapolis: Eli Lilly and Company; 2010.
60. Novartis. Clozaril (clozapine): package insert. East Hanover: Novartis; 2010.
61. Vermeulen A, Piotrovsky V, Ludwig EA. Population pharmacokinetics of risperidone and 9-hydrozyrisperidone in patients with acute episodes associated with bipolar I disorder. J Pharmacokinet Pharmacodyn. 2007;34:183-206.
62. Botts S, Diaz F, Santoro V, et al. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1453-8.
63. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia. Clin Pharmacokinet. 2009;48:585-600.
64. Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry. 2007;68:1540-5.
65. Cherma MD, Reis M, Hägg S, Ahlner J, Bengtsson F. Therapeutic drug monitoring of ziprasidone in a clinical setting. Ther Drug Monitor. 2008;30:682-8.
66. Wittman M, Hauser H, Köstlbacher A, Hajak G, Haen E. Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice. Neuroendocrinol Lett. 2010;31:203-7.
67. DeVane CL, Nemeroff CB. An evaluation of risperidone drug interactions. J Clin Psychopharmacol. 2001;21:408-16.
68. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol. 2006;58:871-85.
69. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine. Clin Pharmacokinet. 2001;40:508-22.
70. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol. 1999;39:297-309.
71. Sopko MA, Ehret MJ, Grgas M. Desvenlafaxine: another "me too" drug? Ann Pharmacother. 2008;42:1439-46.
72. Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D5 substrate desipramine in healthy adults. J Clin Pharmacol. 2009;49:219-28.
73. Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine. Clin Pharmacokinet. 2011;50:281-94.
74. Hendset M, Molden E, Enoksen TB, Refsum H, Hermann M. The effect of coadministration of duloxetine on steady-state concentrations of risperidone and aripiprazole: a study based on therapeutic drug monitoring data. Ther Drug Monit. 2010;32:787-90.
75. Sanatoro V, D'Arrigo C, Spina E, Mico U, Muscatello MR, Zoccali R. Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine, and risperidone in patients with psychotic disorders. J Clin Psychopharmacol. 2010;30:634-6.
76. Van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1998;29(suppl. 1):1-9.
77. Fleishaker JC, Huist LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 1994;46:35-9.
78. DeVane CL. Cyclic antidepressants. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, editors. Applied pharmacokinetics and pharmacodynamics. Baltimore: Lippincott, Williams; 2006. p. 781-812.
79. Centorrino F, Bladessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry. 1994;151:123-5.
80. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry. 1996;153:820-2.
81. Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Gatti G, Perucca E. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic interaction. J Clin Psychopharmacol. 2002;22:419-23.
82. Olesen OV, Linnet K. Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol. 2000;20:35-42.
83. Chang WH, Lin SK, Lane HY, Wei FC, Hu WH, Lam YWF, Jann MW. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:723-9.
84. Fang J, Counts RT, McKenn KF, Baker GB. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn-Schmiedeberg Arch Pharmacol. 1998;358:592-9.
85. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol. 1994;14:279-81.
86. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16:368-74.
87. Chang WH, Augustin B, Lane HY, Zumbrunnen T, Liu HC, Kazmi Y, Jann MW. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology. 1999;145:91-8.
88. Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry. 2000;61:594-9.
89. Weigmann H, Gerek S, Zeisig A, Müller M, Härtter S, Hiemke C. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 2001;23:410-3.
90. Liu CC, Lane HY, Huang MC, et al. Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol. 2004;44:1385-90.
91. Hiemke C, Pelel A, Jabarin M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol. 2002;22:502-8.
92. Albers LJ, Ozdemir V, Marder SR, et al. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements. J Clin Psychopharmacol. 2005;25:170-4.
93. Matsumoto R, Kitabayashi Y, Nakatomi Y, Tsuchida H, Fukui K. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. Am J Psychiatry. 2005;162:812.
94. Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia A. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit. 2001;23:223-7.
95. Saito M, Yasui-Furukori Y, Nakagami T, Furukori H, Kaneko S. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol. 2005;25:527-32.
96. Spina E, D'Arrigo C, Migliardi G, Morgante L, Zoccali R, Ancione M, Madia A. Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit. 2004;26:386-90.
97. De Leon J. Atypical antipsychotic dosing: the effects of co-medication with anticonvulsants. Psychiatric Serv. 2004;55:125-8.
98. Rosaria Muscatello M, Pacetti M, Cacciola M, et al. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia. 2005;46:771-4.
99. Tiihonen J, Variainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry. 1995;28:26-8.
100. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry. 1997;171:109-12.
101. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine and valproate. Ther Drug Monit. 2000;22:481-5.
102. Ono S, Mihana K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship to with CYP2D6 genotypes. Psychopharmacology. 2002;162:50-4.
103. Spina E, Scordo MG, Avenoso A. Perucca E. Adverse drug interaction between risperidone and carbamazepine in a patien with chronic schizophrenia and deficient CYP2D6. J Clin Psychopharmacol. 2001;21:108-9.
104. Lucas RA, Gilfillian DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol. 1998;54:639-43.
105. Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F. Therapeutic drug monitoring data on olanzapine and its N-desmethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002;24:518-26.
106. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedications. Ther Drug Monit. 1999;21:87-90.
107. Linnet K, Olesen OV. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit. 2002;24:512-7.
108. Licht RW, Olesen OV, Friis P, Lausten T. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine. J Clin Psychopharmacol. 2000;20:110-2.
109. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2005;61:58-69.
110. Nicki-Jockschat T, Paulzen M, Schneider F, Grözinger M. Drug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepine. Clin Neuropharmacol. 2009;32:55.
111. Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Lauren A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol. 2000;49(Suppl. 1):65S-70S.
112. Citrome L, Macher JP, Salazar DE, Mallikaarjun S, Boulton DW. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol. 2007;27:279-83.
113. Nakamura A, Mihara K, Nagai G, Suzuki T, Kondo T. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit. 2009;31:575-8.
114. Reimer A, Skogvoll E, Sund JK, Spigest O. Drug interaction between lamotrigine and psychoactive drugs. J Clin Psychopharmacol. 2005;25:342-8.
115. Spina E, D'Arrigo C, Migliardi G, et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone, and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit. 2006;28:599-602.
116. Jann MW, Hon YY, Shamsi SA, Zheng J, Awad EA, Spartlin V. Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. Pharmacotherapy. 2006;26:627-33.
117. Sidhu J, Job S, Bullman J, Fracnis E, Abbott R, Ascher J, Theis JGW. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br J Clin Pharmacol. 2006;61:420-6.
118. Schieber FC, Boulton DW, Balch AH, Croop R, Mallikaarjun S, Benson J, Carlson BX. A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. Hum Psychopharmacol Clin Exp. 2009;24:145-52.
119. Facciola G, Avenoso A, Spina E, Perucca E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit. 1998;20:628-30.
120. Lane HY, Su KP, Chang WH, Jann MW. Elevated plasma clozapine concentrations after phenobarbital discontinuation. J Clin Psychiatry. 1998;59:131-3.
121. Wong YWJ, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol. 2001;21:89-93.
122. Wen X, Wang JS, Kivisto KT, et al. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52:533-47.
123. Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Dispos Metab. 2007;35:1032-41.
124. Facciola G, Avenoso A, Scordo MG, Madia A, Ventimiglia A, Perucca E, Spina E. Small effect of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia of affective disorders. Ther Drug Monit. 1999;21:335-41.
125. Longo LP, Salzman C. Valpoic acid effect on serum concentrations of clozapine and norclozapine. Am J Psychiatry. 1995;152:650.
126. Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry. 1994;36:487-8.
127. Bergemann N, Kress KR, Abu-Tair F, Frick A, Kopitz J. Valproate lowers plasma concentration of olanzapine. J Clin Psychopharmacol 2006;26:432-4.
128. Spina E, D'Arrigo C, Santoro V, et al. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther Drug Monit. 2009;31:758-63.
129. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45:89-93.
130. Markowitz JS, Gill HS, DeVane CL, Minzter JE. Fluoroquinolone inhibition of clozapine metabolism. Am J Psychiatry. 1997;153:881.
131. Sanbhi R, Purl R, Jones G. Interaction of clozapine and ciprofloxacin: a case report. Eur J Clin Pharmacol. 2007;63:895-6.
132. Brouwers EEM, Söhne M, Kuipers S, et al. Ciprofloxacin strongly inhibits clozapine metabolism. Clin Drug Invest. 2009;29:59-63.
133. Raaska K, Neuvonen PJ. Ciprofloxacin increase serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol. 2000;56:585-9.
134. Funderberg LG, Vertrees JE, True JE, Miller AL. Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry. 1994;151:1840-1.
135. Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC. Erythromycin-induced clozapine toxic reactions. Arch Intern Med. 1996;156:675-7.
136. Hägg S, Spigset O, Mjörndal T, Granberg K, Persbo-Lundqvist G, Dahlqvist R. Absence of interaction between erythromycin and a single dose of clozapine. Eur J Clin Pharmacol. 1999;55:221-6.
137. Markowitz JS, DeVane CL. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentrations. J Clin Psychopharmacol. 1999;19:289-91.
138. Li KY, Li X, Cheung ZN, Zhang BK, Peng WX, Li HD. Effect of erythromycin on metabolism of quetiapine. Eur J Clin Pharmacol. 2005;60:791-5.
139. Schulz-DuBois C, Schulz-DuBois AC, Bewig B, Gerstner I, Aldenhoff JB, Cascorbi I, Ufer M. Major increases of quetiapine steady-state plasma concentration following coadministration of clarithromycin: confirmation of the pharmacokinetic interaction potential with quetiapine. Pharmacopsychiatry. 2008;41:258-9.
140. Lane HY, Chiu CC, Kazmi Y, Desai HD, Lam YWF, Jann MW, Chang WH. Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo. Drug Metab Drug Interact. 2001;18:263-78.
141. Raaska K, Neuvonen PJ. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol. 1998;54:167-70.
142. Chetty M, Murray M. CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab. 2007;8:307-13.
143. Jung SM, Kim KA, Cho HK, Jung IG, Park PW, Byun WT, Park JY. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005;78:520-8.
144. Angelini MC, MacCormack-Gagnon J, Dizio S. Increase in plasma levels of clozapine after addition of isoniazid. J Clin Psychopharmacol. 2009;29:190-1.
145. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetic and other interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35:275-91.
146. Eagling VA, Black DV, Barry DG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors ritonavir, saquinavir, and indinavir. Br J Clin Pharmacol. 1997;44:190-4.
147. Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol. 2002;22:366-70.
148. Kelly DV, Béïque LC, Browner MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother. 2002;36:827-30.
149. Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy. 2009;29:1386-91.
150. Geraci M, McCoy SL, Crum PM, Patel R. Antipsychotic induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction. Int J Emerg Med. 2010;3:81-4.
151. Hantson P, DiFazio VD, Wallenacq P. Toxickinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose. Drug Metab Lett. 2010;4:7-8.
152. Aung GL, O'Brien JG, Tien PG, Kawando LS. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother. 2010;44:1850-4.
153. Symanski S, Lieberman JA, Picou D, Masiar S, Cooper TA. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry. 1991;52:21-2.
154. Frick A, Kopitz J, Bergemann N. Omeprazole reduces clozapine plasma concentrations. Pharmacopsychiatry. 2008;36:121-3.
155. Lancelin F, Bourcier E, Masson V, Lemeille Y, Brovedani S, Pauble P, Piketty M. Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study. Ther Drug Monit. 2010;32:757-61.
156. Uehlinger C, Crettol S, Chassot P, Brocard M, Koeb L, Brawand-Amey M, Eap CB. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol. 2007;27:273-8.
157. Hasselstrom J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metab Drug Interact. 2006;21:187-211.
158. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications. CNS Drugs. 2001;15:469-94.
159. Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H. The effect of variable cigarette consumptions on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62:1049-53.
160. Ng W, Uchida H, Ismali Z, et al. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit. 2009;31:360-6.
161. Cromac I, Brown A, Creasey S, Ferriter M, Huckstep B. A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine. Acta Psychiatr Scand. 2010;121:393-7.
162. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48:157-65.
163. Diaz FJ, Santoro V, Spina E, Cogollo M, Rivers TE, Botts S, de Leon J. Estimating the size of the effect of comedications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008;41:81-91.
164. Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther. 2009;26:739-48.
165. Hägg S, Spigset O, Mjörndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2000;49:59-63.
166. Odom-White A, de Leon J. Clozapine levels and caffeine. J Clin Psychiatry. 1996;57:175-6.